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Abstract: Anderson–Fabry disease (AFD) is an X-linked lysosomal storage disorder, caused by
deficiency or absence of the alpha-galactosidase A activity, with a consequent glycosphingolipid
accumulation. Biomarkers and imaging findings may be useful for diagnosis, identification of an
organ involvement, therapy monitoring and prognosis. The aim of this article is to review the current
available literature on biomarkers and imaging findings of AFD patients. An extensive bibliographic
review from PubMed, Medline and Clinical Key databases was performed by a group of experts from
nephrology, neurology, genetics, cardiology and internal medicine, aiming for consensus. Lyso-GB3
is a valuable biomarker to establish the diagnosis. Proteinuria and creatinine are the most valuable
to detect renal damage. Troponin I and high-sensitivity assays for cardiac troponin T can identify
patients with cardiac lesions, but new techniques of cardiac imaging are essential to detect incipient
damage. Specific cerebrovascular imaging findings are present in AFD patients. Techniques as
metabolomics and proteomics have been developed in order to find an AFD fingerprint. Lyso-GB3 is
important for evaluating the pathogenic mutations and monitoring the response to treatment. Many
biomarkers can detect renal, cardiac and cerebrovascular involvement, but none of these have proved
to be important to monitoring the response to treatment. Imaging features are preferred in order to
find cardiac and cerebrovascular compromise in AFD patients.
Keywords: Anderson–Fabry disease; biomarkers; imaging; diagnosis; Lyso-Gb3; renal involvement;
cardiac involvement; cerebrovascular involvement; proteomics; metabolomics
1. Introduction
Anderson–Fabry disease (AFD), an X-linked lysosomal storage disorder, is caused by the
deficiency or the absence of the alpha-galactosidase A (α-Gal-A), which leads to an accumulation of
globotriaosylceramide/ceramide trihexoside (Gb3) and other glycosphingolipids in the lysosomes
of several cells types, mainly the endothelial, neuronal, cardiac and renal cells. Its heterogeneous
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and nonspecific presentation is associated with a delay in diagnosis of approximately 15 years.
Some patients present a late-onset attenuated phenotypes, with the predominant involvement of an
organ [1].
The diagnosis of AFD is established by the determination of α-Gal-A activity and/or by the GLA
gene (gene coding for α-galactosidase A) analysis. In male patients with classical manifestations
of the disease, the diagnosis can be confirmed if the activity of α-Gal-A is not detectable or less
than 5% of the expected value. However, in male individuals with attenuated phenotypes and in
heterozygous female patients, the residual enzyme activity can be significant (although less than
the normal for the general population), and, in these cases, the GLA gene analysis is required for a
definitive diagnosis [2,3].
Moreover, the response to the enzyme replacement therapy (ERT) is not only highly unpredictable
but also difficult to monitor in terms of efficacy.
In this context, the identification of reliable and validated biomarker(s), defined according to
the National Institutes of Health Biomarkers Definitions Working Group, as “a characteristic that
is objectively measured and evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to a therapeutic intervention” is crucial [4]. In AFD,
biomarkers may be useful for several purposes: diagnosis—distinguishing between pathogenic
mutations and non-pathogenic mutations or polymorphisms; early identification of a specific
organ involvement or damage; and prognosis—identifying patients at greater risk of progression
and response to treatment.
Typical cardiac and cerebrovascular image features have been described in AFD patients.
The aim of this manuscript is to review the current literature on biomarkers and imaging findings in
AFD patients.
2. Biomarkers and Imaging Findings
We can identify two main types of biomarkers in lysosomal storage disorders: (1) molecules
whose accumulation results from a defective lysosomal function (increased substrates due to an
enzymatic defect); (2) molecules produced by the cells in response to the lysosomal storage, reflecting
the effect of the primary defect on the cell, tissue or organ function [5]. Although the diagnosis
of AFD to be based on the evaluation of the activity of α-Gal-A and analysis of the GLA gene, the
determination of biomarkers may be useful, namely in women with very high clinical suspicion and
no mutations identified or presence of mutations of uncertain significance in GLA gene analysis and
in men with residual enzyme activity (>5% of normal) and unidentified mutations or presence of
mutations of uncertain significance [2]. In addition to biochemical biomarkers, the imaging findings,
mainly cardiac and neurologic, are extremely important for the diagnosis and follow-up of the
organ injury.
2.1. Biomarkers
2.1.1. Gb3 and LysoGB3
Molecules like Gb3 and Lyso-Gb3, which accumulate due to the enzymatic defect, have been
extensively studied for diagnostic purposes and considered as a possible biomarker of AFD (Table 1).
Gb3 is the substrate of the enzyme α-Gal-A [6] and its urinary or plasma concentration has been,
for a long time, considered as a possible diagnostic biomarker of the AFD. Urinary excretion has
been identified as the gold standard with better sensitivity to identify AFD patients than the plasma
Gb3 levels [7]. However, both presented several limitations. In two studies, including male and
female patients with classical and attenuated phenotypes, urinary Gb3 was elevated in all classically
affected males, but slightly increased in only 50% of males with attenuated phenotype. In women,
97% of those with mutations associated with the classical phenotype had high urinary Gb3, which
was not observed in women with mutations associated with the attenuated phenotype [7]. In a study
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published in 2010, a clear overlap in the plasma Gb3 values was observed between the attenuated
phenotype males, the heterozygote females and the healthy controls [8,9]. In addition, there is no
evidence of its value in assessing the efficacy of ERT or in renal prognosis [10]. Thus, a measurement
of urinary or plasma Gb3 is not relevant for diagnosis and allows only reliable identification of male
patients with classical phenotype, in which the enzyme activity is absent or very low.
In 2008, a new biomarker, a product of the Gb3 deacylation, globotriaosylsphingosine (Lyso-Gb3)
has been identified as a hallmark of the AFD [11]. In this first study, a huge increase in plasma
Lyso-Gb3 has been reported in all of the affected males and in the great majority of the affected
females, as well as in the plasma and tissues of Fabry mice. Lyso-Gb3 has also been implied in the
AFD pathogenesis because the “in vitro” exposure of smooth muscle cells to Lyso-Gb3 promoted
its proliferation [11] and the incubation of podocytes with Lyso-Gb3 induced the expression and
production of extracellular matrix compounds, like fibronectin or collagen type IV [12]. In a study
of 92 AFD patients, Lyso-Gb3 was increased in all male patients (including those with attenuated
phenotypes) and of the 55 women included in the study, 53 had also increased Lyso-Gb3 (although to
a lesser extent than men). Only two young asymptomatic carriers, aged 5 and 7 years old, had
Lyso-Gb3 within the normal range [9]. These results were corroborated in another study in which
males and females showed an increased Lyso-Gb3 plasma [8]. The first study [9] also demonstrated
that the plasma Lyso-Gb3 was not increased in 11 patients carrying GLA mutations not unequivocally
linked to AFD, namely p.R112H and p.P60L. These results suggest that measurement of Lyso-Gb3 in
plasma could be an additional useful evaluation for the confirmation of AFD in individuals with GLA
mutation of unknown significance.
In a study of 124 patients, of which 72 patients with mutations described earlier (55 patients
with classical mutations and clinical presentation and 17 with atypical mutations and attenuated
phenotypes) and the remaining 52 patients with new mutations, all patients with atypical mutations
had levels Lyso-Gb3 lower than any of the patients with classical Fabry disease (n = 55) and a cut-off
value of 2.7 ng/mL separated the two groups. Six of the 52 patients with new mutations without
classical organ involvement had Lyso-Gb3 < 2.7 ng/mL, unlike patients with new mutations and
Lyso-Gb3 > 2.7 ng/mL who had classical manifestations of Fabry. Based on these findings, the
authors proposed a redefinition of the diagnosis of Fabry disease based on: (1) mutation information
from the GLA gene; (2) the level of Lyso-Gb3; and (3) the typical symptoms of Fabry and organ
involvement [13].
With nano-liquid chromatography—tandem mass spectrometry (a more sensitive technique
allowing the detection of extremely low concentrations of Lyso-Gb3), in patients with mutations
not unequivocally linked to AFD (p.R112H and p.M296I) the Lyso-Gb3 was lower than in most of
the AFD patients with other mutations, but higher than in those with functional variants or healthy
subjects [14].
In a case control study including classical AFD male and female patients treated with different
ERT regimes, all patients had high plasma Lyso GB3 levels before ERT, with marked decline after three
months of different ERT regimens, especially in men and subsequent stabilization [15].
Urinary Lyso-Gb3 appears to be particularly useful in the analysis of suspected cases of AFD, but
has not been correlated with the degree of renal involvement [16]. Moreover, Rombach et al. found
that there was no apparent correlation between the plasma Lyso-Gb3 concentration and renal failure,
microalbuminuria and proteinuria [9].
2.1.2. Biomarkers of Kidney Injury
Biomarkers of kidney injury are mainly found in urine and their excretion reflects abnormal
nephron function secondary to Fabry disease.
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Proteinuria
The presence of albuminuria/proteinuria is one of the first signs of the renal damage in AFD and
is the current gold-standard biomarker for the Anderson–Fabry nephropathy. In classically affected
patients, it usually emerges in the second or third decade of life and contributes to the progression of
the AFD nephropathy, and it is an independent risk factor for the progression of kidney disease in both
treated and untreated patients [1,17–20]. Despite the intense research to discover other biomarkers,
in addition to proteinuria and creatinine, no other biomarker proved to be useful for the follow-up
of Anderson–Fabry nephropathy [10]. However, proteinuria/albuminuria is not an early marker of
renal damage, since in the early stages of AFD nephropathy, tubular reabsorption may outweigh
the increased excretion of albuminuria. In addition, there are several reports of severe storage in
endothelial, glomerular, tubular and interstitial cells in normoalbuminuric patients with normal
glomerular filtration rate (GFR).
Urinary Podocytes
Podocytes are particularly affected in AFD [21] as they continuously accumulate α-Galactosidase
A substrates, which may lead to morphologic and functional changes [22]. Synaptopodin is an
actin-associated protein highly expressed in foot processes of podocytes [22]. It regulates the
podocyte contraction by interacting with the actin filaments [23], preventing the reorganization
of the cytoskeleton into a migratory phenotype [24]. A reduction in the cellular synaptopodin
concentration has been associated with foot process effacement and with proteinuria [23]. It has
been speculated that the mechanical stress caused by the accumulation of Gb3 could change the
distribution of synaptopodin [25]. In addition, actin and actin filaments interact mainly with the β1 or
β3 subunits of the integrin, increasing the contraction and migration of podocytes [23] [23], and leading
to their detachment and to the urinary loss of podocytes, a phenomenon known as podocyturia [26].
Thrimarchi et al., using synaptopodin as a marker of podocyte count in immunofluorescence, showed
that the AFD patients display high levels of podocyturia comparing to the normal population. In
addition, patients with untreated AFD presented significantly higher levels of podocytria even without
proteinuria when compared to patients submitted to ERT, suggesting that podocyturia may precede
proteinuria. The presence of lower podocyturia, higher proteinuria and a worse renal function in
treated patients may be related to the fact that the ERT was started in advanced stages of the AFD [22].
Pereira et al. used immunofluorescence staining of podocalyxin to identify urinary podocytes and
found that the average number of podocytes in the urine of AFD patients was significantly higher than
in the healthy controls and found a positive correlation between podocyturia and albumin: creatinine
ratio [27].
Cystatin-C
Cystatin-C is a protein produced by all nucleated cells and freely filtered by the glomerulus.
In normal conditions, Cystatin-C is reabsorbed and catabolized by the tubular epithelial cells,
preventing it from re-entering in the bloodstream or in the urine. In an observational study,
Torralba-Cabeza et al. suggested that the Cystatin-C concentration is a superior and more sensitive
marker than serum creatinine to detect early renal involvement or small decreases in the glomerular
filtration rate in AFD patients of both genders, which can be important to evaluate the efficacy of
the ERT and to be a good prognostic marker [28]. These findings corroborated the Feriozzi et al.
study results, which demonstrated that, in patients with Fabry nephropathy, Cystatin-C seems to be
more sensitive than serum creatinine for detecting GFR early changes during ERT [29]. It would be
interesting to confirm the value of Cystatin-C in the GFR estimation by comparing it to a gold standard
method using radionucleotides.
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Tubular Proteins
Abnormal urinary excretion of some proteins may indicate a commitment of the tubular
reabsorption or of the excretion functions. In the AFD patients, an increase in N-acetyl-β-D-
glucosaminidase, β-2-microglobulin and in these urinary proteins have been reported [10].
Uromodulin is a protein normally excreted on the thick ascending limb of Henle’s loop. Significant
quantitative and qualitative changes were observed in the excretion of uromodulin in patients with
AFD, that is, a gradual decrease in excretion accompanied in some cases by an aberrant uromodulin
without the C-terminal part after the K432 residue. This abnormal pattern is normalized in all patients
undergoing ERT [30].
In a study with 13 female AFD patients on ERT for more than one year, Prabakaran et al. found
that the ERT was associated with a significant decrease of the tubular damage marker α1-microglobulin
and a trend towards a decrease of retinol-binding protein [31].
Bikunin
Bikunin, also named urinary trypsin inhibitor, is a serine protease inhibitor present in plasma and
in many tissues, and excreted in the urine. Urine bikunin levels are significantly higher in the AFD
patients with renal impairment when compared to the healthy controls. Therefore, in patients with
AFD without an overt nephropathy, the urine bikunin levels are not elevated and, for that, are not a
good marker of an incipient nephropathy. Moreover, the bikunin origin and the mechanisms by which
its urinary levels are elevated remain unclear and deserve further evaluation [32].
2.1.3. Biomarkers of Cardiac Injury
N-Terminal Pro-Brain Natriuretic Peptide
Brain natriuretic peptide and the N-terminal fragment of its pro-hormone (NT-proBNP) are
important in the diagnosis and prognosis of heart failure. In AFD patients, plasma NT-proBNP
correlates with symptom cardiac class, echocardiographic findings of left ventricular (LV) filling
pressure [33] and with severity of the cardiomyopathy [34]. NT-proBNP was also useful to detect
subclinical cardiac disease in AFD, as it is increased in patients without echocardiographic evidence of
LV hypertrophy (LVH) [33].
Troponins
Cardiac troponins are validated and available laboratory biomarkers of cardiac muscular
damage. In a study involving 14 subjects (seven under ERT), 21% (two females and one male)
had consistently elevated values of troponin I (TrI), related with a higher left ventricle posterior
wall diameter on Cardiac Magnetic Resonance (CMR), a late gadolinium enhancement (LGE) and
proteinuria [35].
The new generation of high-sensitivity assays for cardiac troponin T (hs–cTnT) allows the
identification of minimal cardiac damage [36] and has been associated with poor outcomes in ischemic
and non-ischemic heart disease [37]. It also seems to allow a differentiation between infiltrative and
hypertrophic cardiomyopathy (HCM). In a case control study enrolling 35 patients with sarcomeric
HCM and 11 patients with infiltrative cardiomyopathy (eight patients with cardiac amyloidosis and
three patients with AFD), the serum hs-cTnT was significantly higher in the infiltrative cardiomyopathy
patients [38].
Recently, Seydelmann and his colleagues, in a prospective cohort of 75 patients, showed a strong
positive correlation between hs-cTnT, LVH and the amount of left ventricular fibrosis (detected by a
late enhancement in CMR). They also found that an advanced kidney dysfunction was significantly
associated with an elevated hs-cTnT level. In the same report, they retrospectively analyzed data from
58 patients and found, over a follow-up period of 3.9± 2.0 years, that patients with an elevated baseline
hs-cTnT (>14 ng/L) had a significantly increase in fibrosis deposition, a significant decrease in left
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ventricular wall thickness and a reduction of the ejection fraction during the follow-up. This suggest
that the left ventricular wall thinning might be associated with the intramural fibrosis replacement
and heart disease progression, which is confirmed by the ejection fraction reduction during the
follow-up [39].
Pro-Inflammatory Cytokines
Pro-inflammatory cytokines may contribute to the progression of cardiac failure, promoting
further cardiac inflammation and interstitial fibrosis [40]. Chen et al. showed, in a comparative
study with 25 AFD patients with LVH under 12 months of ERT, 25 AFD patients without
LVH and 25 healthy controls, a significant improvement in the transthoracic echocardiography
parameters (left ventricular mass (LVM), LVM index (LVMI), interventricular septal thickness),
in the Lyso-Gb3 and pro-inflammatory cytokine levels (interleukin (IL)-6, IL-2, IL-1b, tumour
necrosis factor-α, intercellular adhesion molecules, soluble vascular cell adhesion molecule, and
monocyte chemoattractant protein 1 (MCP-1)) after ERT. Very important changes in IL-6, MCP-1,
and in the Lyso-Gb3 levels were positively correlated with an improvement in the LVMI. Therefore,
IL-6 and MCP-1 can be used as potential markers for the monitoring of the outcomes of ERT in
the AFD population [41]. Another case-control study found that serum myeloperoxidase (MPO)
was significantly increased in a large group of AFD male patients, but not significantly in female
patients. They also found that an elevated serum MPO level is a significant risk factor for developing
vascular-related events (stroke, myocardial infarction, toe infarct, end-stage renal disease and death
related to AFD) in subsequent years [42].
Biomarkers of the Extracellular Matrix Turnover
Shah et al. compared the levels of important mediators of the extracellular matrix turnover, matrix
metalloproteinases (MMPs) and their endogenous inhibitors and tissue inhibitors of metalloproteinases
(TIMPs), in 29 AFD patients and 21 controls. MMP-9 levels were elevated in the AFD patients, but
there were no differences in the TIMP-1 and TIMP-2 levels. MMP-9 levels were correlated with the
clinical markers of the disease severity including the fractional shortening and the overall disease
severity [43].
Kramer et al. in a study involving 73 patients followed for 4.8 ± 2.2 years, and found that the
collagen biomarkers (serum procollagen type III aminoterminal propetide, serum procollagen type
I carboxyterminal propetide and serum collagen type I carboxyterminal telopeptide) were elevated
in patients with and without LGE in CMR but were not correlated with LGE amount [44].
2.1.4. Biomarkers of the Cerebrovascular Injury
No unequivocal serum biomarkers for early detection, risk stratification or for monitoring of the
cerebrovascular disease progression are known [45]. There is a weak correlation between the serum
Cystacin-C and the central nervous system (CNS) pathology in males [28]. In females, plasma Lyso-Gb3
correlates with the white matter lesions (WML) severity [9]. Other potential serum biomarkers related
to the endothelial dysfunction and inflammation are the nitric oxide, the soluble vascular cell adhesion
molecule-1, the high-sensitivity C-reactive protein, the tumour necrosis factor-α, the IL-6 and the
P-selectin [40,46].
Diseases 2017, 5, 15 7 of 17
Table 1. Molecular and Biochemical Markers of Anderson-Fabry Disease.
Organ Specificity Biomarker Plasma/Urine Value Availability Response to ERT
Nonspecific Gb3 [7–9,15] Plasma/Urine Diagnosis in classic male patients Clinical work-up Useless [7]
Lyso-Gb3 [8–10,12–14] Plasma Increased in all male AFD patients and in most females.Confirmation in mutations of unknown significance Clinical work-up Decreased
Kidney
Proteinuria [1,17–20] Urine Glomerular damage Clinical work-up Decreased [47]
Podocyturia [22–27] Urine Glomerular damage Clinical work-up Decreases
Creatinine [15] Plasma Change in GFR Clinical work-up Decreased [48] mean slop GFR
Cystatin C [9,28] Plasma Early change in GFR Clinical work-up Not studied
N-acetil-β-D- glucosaminidase [15] Urine Tubular damage Experimental studies Not studied
β2-microglobulin [15] Urine Tubular damage Experimental studies Decreases
Uromodulin [30] Urine Tubular damage Experimental studies Not studied
α1-microglobulin [31] Urine Tubular damage Experimental studies Decreases
Retinol-binding Protein [31] Urine Tubular damage Experimental studies Decreases
Bikunin [32] Urine Experimental Not studied
Heart
NT-proBNP [33,34] Plasma Elevated in subclinical disease. Correlates withcardiomyopathy severity Clinical work-up Not studied
Troponin [35] Plasma Correlates with higher LV posterior wall diameter Clinical work-up Not studied
Hs-cTnT [38,39] Plasma Correlates with LVH and amount of left ventricular fibrosis Clinical work-up Not studied
IL 6 [41] Plasma Cardiac damage Experimental studies Decreases
MCP 1 [41] Plasma Cardiac damage Experimental studies Decreases
MMP-9 [43] Plasma Cardiac damage Experimental studies Not studied
Gb3 - globotriaosylceramide; Lyso-Gb3 – globotriaosylsphingosine; NT-proBNP - N-terminal fragment of the brain natriuretic peptide pro-hormone; Hs-cTnT - high-sensitivity assays for
cardiac troponin T; IL6 – interleukin 6; MCP 1 - monocyte chemoattractant protein 1; MMP-9 - matrix metalloproteinase 9.
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2.1.5. Metabolomics
In searching for biomarkers that encompass the above-mentioned pitfalls, the metabolomics
approach has been employed using tandem mass spectrometry platforms. It has been possible to
identify several metabolites over expressed in the AFD patients, in plasma and urine, all of them
with a structural relation to Gb3, the principal α-Gal-A substrate. Most studies reported Lyso-Gb3
analogues/isoforms, which differ from Lyso-Gb3 in their sphingosine moiety [49–51]. Recently, the
presence of several Galabiosylceramide (Ga2) analogues in urine was reported. Interestingly, the
type and the relative proportion of the structural variants present some significant differences from
their Gb3 counterparts, raising some questions about possible and different synthesis or degradation
pathways [52].
Despite the promising results of these studies, the candidate biomarkers still need to overcome
some limitations: in some studies, only male patients were analyzed; others included female patients,
and the difference to controls was not as striking in addition to the need to test the mutations carriers
that are known to cause little increase in the metabolites concentration. Furthermore, no results have
been reported in the treatment follow-up.
2.1.6. Proteomics
In the AFD, the proteomics approach has also been applied to find biomarkers that might allow
the measurement of the disease severity, the prognosis and the evaluation of the therapy effects, in
addition to the possibility to give some insights on the pathophysiology of the disease.
A preliminary study performed by Cigna et al. compared peripheral blood mononuclear cells
from the proteome profiles of eight patients and six controls, using two-dimensional electrophoresis
and subsequent analysis of the detected and differentially expressed proteins by a matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry. All proteins that were found to have
significant expression differences (either up or down regulation) play a role in the mechanisms that
may be associated with the pathophysiology of the AFD [53].
Urine proteome of the AFD patients was studied by Matafora et al. and allowed the identification
of several proteins with an altered expression—among them uromodulin, prostaglandin H2
D-isomerase and prosaposin—that are known to play a role in the processes that might be involved
in the disease pathophysiology, as inflammation and glycosphingolipid metabolism. Moreover, this
study allowed for discriminating female patients from controls and demonstrated the “normalization”
of some protein levels during the therapy, which is a valuable achievement [54].
Vojtová et al. found that the AFD does not lead to the formation of new proteins or degradation
products, although quantitative changes were found in urine such as: substantially increased Ig
kappa chain V-III, complement-C1q tumour necrosis factor-related protein and prostaglandin H2
D-isomerase [55].
Another study, involving 10 paediatric Fabry patients, found that, following 12 months of ERT,
prosaposin was the only protein significantly reduced and that another GM2 activator protein was also
decreased in urine [56].
The upregulation of the prostaglandin H2 D-isomerase and of prosaposin in the urine of ADF
patients was confirmed in another study. A decrease on their concentration was observed after the
ERT institution, demonstrating a potential usefulness of these markers in the monitoring of the ERT
response [54].
Hollander et al. discovered plasma biomarkers by using a mass spectrometry iTRAQ proteomic
approach [57]. Based on multiple reaction monitoring, an eight-protein biomarker panel was identified
(22 kDa protein, afamin, α-1 antichymotrypsin, apolipoprotein E, β-Ala His dipeptidase, haemoglobin
α-2, isoform 1 of sex hormone-binding globulin, and peroxiredoxin 2), which was very specific and
sensitive to diagnose male AFD patients. In female AFD patients, a nine-biomarker panel of proteins
was identified, with only three proteins, apolipoprotein E, haemoglobin α-2 and peroxiredoxin 2,
common to both genders, suggesting the existence of a gender-specific alteration in the plasma
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biomarkers of the patients with AFD. This is also supported by the fact that haemoglobin α-2 (one of
the proteins common to both panels) presents different gender “behaviour”: is upregulated in females
and downregulated in males, when compared to the matched controls. The other proteins identified in
the female panel (actin α-cardiac muscle 1, isoform 1 of gelsolin, kallistatin, paraoxonase 1, pigment
epithelium-derived factor, protein Z-dependent protease inhibitor) are associated with the protease
activity, the antioxidant effects, as well as with the cytoskeletal composition, which is a unique feature
when compared with the whole AFD group [57]. Presently, the heterozygous females represent the
most challenging AFD patient group. In fact, most of the affected females develop a clinically significant
disease; however, their constellation of symptoms is frequently variable [58–60]. The biomarker panels,
such as the nine-peptide panel, may be very helpful in the case of ambiguous mutations, or genetic
lesions that confound the genetic analysis such as large deletions [13,61].
2.2. Imaging Findings
2.2.1. Imaging Tools for the Assessment of Fabry’s Cardiomyopathy
Echocardiography
Conventional two-dimensional (2D) echocardiography is the standard imaging tool for identifying
cardiac involvement in AFD, but it is not suitable to detect subtle myocardial dysfunction in the early
course of AFD.
Advanced echocardiography techniques, like Doppler tissue imaging (DTI), strain and strain
rate speckle-tracking (ST) based echocardiography, added new insights into several forms of
cardiomyopathy, particularly in AFD [62–67]. These techniques have been used to assess the early
cardiac involvement that precedes the LVH and fibrosis.
Diagnosis of incipient cardiac involvement is suspected if, in DTI, lower early diastolic tissue
Doppler velocities, longer isovolumic relaxation time, shorter isovolumic contraction time (IVCT) and
lower peak systolic wall motion velocity are observed.
Zamorano et al., in a prospective observational study with 66 patients performing an
echocardiogram at the baseline and then periodically, found an increase in interventricular septum
thickness associated with the decrease of the DTI velocities [63]. Pieroni et al. compared three groups
of 10 patients each (α-GLA gene mutations and LVH, α-GLA gene mutations without LVH, and healthy
controls) and observed that all patients with mutations showed a reduced myocardial contraction and
relaxation of the tissue Doppler velocities, independently of the gender and the mutation type. In these
patients, the DTI abnormalities were proportional to the increase in the left ventricle filling pressure.
Among the DTI parameters, IVCT ≤ 105 ms was the best predictor for a subclinical involvement, with
a sensitivity of 100% and a specificity of 91% [64]. Furthermore, recent reports have shown that DTI
can detect reduced myocardial contraction and relaxation velocities in patients with familial HCM
before and independently of LVH, being an accurate and sensitive method for identifying subjects
who are positive, for familial HCM mutations [62].
2D ST imaging is also a non-invasive echocardiographic tool for the assessment of the regional
myocardial function [68]. Kramer et al. conducted a cross-sectional study, in a cohort of 101 patients
with AFD and found that LGE was present in 51% of the patients in the posterior and lateral walls,
with a mean volume of 1.2 ± 1.8% of the LVM [69]. In addition, in the 2D ST imaging, the global
peak systolic strain was lower in those patients with myocardial fibrosis and higher rates of fibrosis
were associated with lower global deformation values. This suggested that the systolic strain in the
basal posterior or lateral segments is the most powerful predictor for LGE. Strain values in one of
these segments lower than −12.5% indicate that LGE with a specificity of 97% and a sensitivity of
90%. In addition, patients with strain in those segments higher than +16.5% showed no pathological
LGE (100% specificity and 89% sensitivity). Thus, 2D ST imaging is an easy, reliable, and reproducible
echocardiographic tool for the non-invasive evaluation of the LGE-related functional abnormalities in
patients with AFD.
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New Studies in Cardiac Magnetic Resonance
Imaging studies are important tools for the diagnosis and follow-up of the cardiac involvement in
AFD and the gadolinium-based contrast CMR is the gold standard for the non-invasive detection of
focal fibrosis.
The development of new pulse sequences allowed the measurement of native myocardial T1
(non-contrast myocardial T1) and of T1 after the administration of a gadolinium contrast [70]. Native T1
is known to be higher in fibrosis, oedema and amyloid deposits, and reduced in iron overload and lipid
storage (as occurs in AFD) [71–73]. Measurement of T1 with extracellular gadolinium based contrast
agents gives additional information about the extracellular volume fraction, which is particularly
valuable for the diffuse diseases that are usually more difficult to detect using a conventional late
gadolinium enhancement [71,72]. Pica et al. evaluated the role of the native myocardial T1 mapping
in the early detection of a cardiac involvement in a cohort study of 63 AFD patients (with or without
LVH) and matched healthy controls. Patients with LVH had the septal T1 significantly lower than
the patients without LVH and the healthy controls. Regarding the group of patients without LVH,
48% had reduced T1 mapping values and this subgroup had a lower global longitudinal ST and a
higher left ventricular filling pressure based in E/E′ in advanced echocardiography techniques. These
data suggest that a reduced T1 is a possible biomarker of the cardiac involvement in early stages of
hypertrophy and fibrosis. Based on the T1 mapping, the authors propose four phases of myocardial
AFD: phase 1: normal; phase 2: low T1 and early myocardial dysfunction; phase 3: LVH, low T1;
phase 4: “pseudonormalisation” of T1, fibrosis, heart failure (as extensive fibrosis and scarring showing
a high T1 value) [74].
Positron Emission Tomography and Magnetic Resonance (PET/MR)
In a study involving 13 patents, with simultaneous PET/MR imaging, was possible to distinguish
between mature fibrosis or scars from fibrosis associated with active inflammation allowing functional
and morphologic information. Further studies to evaluate the role of the PET/MR combination in
detecting cardiac involvement are warranted [75].
2.2.2. Imaging Tools for the Assessment of Fabry’s Central Nervous System Injury
Magnetic Resonance Imaging
WML, enlargement and tortuosity of the basilar and vertebrobasilar artery, pulvinar sign,
hippocampus atrophy, transcranial doppler abnormalities in the brain arteries are specific features in
cerebrovascular involvement in AFD patients (Table 2).
WMLs, in the form of single, multiple, or confluent hyperintensities in T2-weighted Magnetic
Resonance Imaging (MRI), are the most common reported image markers of a neurovascular
involvement in the AFD patients. Buechner et al., in a cohort of 43 patients, identified WML in
16 men (64%) and 13 women (72%), despite the absence of overt clinical signs of cerebral disease [76].
The localization pattern is typical of a small vessel disease (subcortical, deep and periventricular white
matter, usually with a symmetrical distribution) and is like the age-related WML [77]. Rare in children
with AFD, the presence and the load of WML increases with age. A longitudinal study of 50 AFD
patients (age 6 to 63) found no lesions in the patients before 26 years old, but at the age of 54 years
old, all patients had some degree of WML. Both genders seem to be equally affected [78]. The WML
load in AFD could be modulated by classical and genetic vascular risk factors and by the presence
of another organ injury. In addition, the WML load was associated with cardiomyopathy and their
severity and progression was associated with a lower glomerular filtration rate [79]. It is important to
state that the WML and the silence infarctions are also often found in young patients with stroke from
other causes and could be entirely absent in young AFD stroke patients [80]. Diffusion tensor imaging
(DTI) proved to detect early white matter abnormalities and could be a potential marker of the disease
progression [81,82].
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Table 2. Imaging findings.
Imaging Exam Characteristic Findings Availability
Cardiac echocardiography
[45,46,49–54]
Lower early diastolic tissue Doppler velocities
Longer isovolumic relaxation time
Shorter isovolumic contraction time
Lower peak systolic wall motion velocity
Lower global peak systolic strain
Lower global deformation values
Clinical work-up
Cardiac MR [55–59] Low T1LGE in the posterior and lateral walls Clinical work-up
Cerebral MR [63–75]
White matter lesions on T2-weighted MRI
Basilar artery dolichoectasia
Pulvinar sign on T1
Hippocampus atrophy
Clinical work-up
Transcranial Doppler [61]
Small vessel disease and abnormal cerebral
autoregulation; posterior cortical
vascular dysfunction
Clinical work-up
PET/MR [60,84]
Cardiac: distinguish scar from fibrosis associated
with active inflammation.
Cerebral: No additional information to MR isolated
Experimental studies
Significant enlargement (dolichoectasia) and tortuousness of the intracranial arteries, in particular
of the basilar artery, is frequently reported in the AFD patients. Fellgiebel et al., using MR angiography
in three age and gender matched groups, demonstrated that the enlarged basilar artery diameters
enabled detecting the AFD patients within a mixed cohort of AFD, stroke patients and healthy
controls [83]. These results were confirmed later in male patients with basilar artery diameter ≥3.2 cm,
which distinguished the AFD patients from controls (sensitivity: 87%, specificity: 86%) but not from
other stroke patients [84]. A recent study of 70 AFD patients also suggested that the vertebrobasilar
dolichoectasia could be an early marker of a neurovascular involvement, being present in 56% of
the men and 35% of the women, identified even in the absence of white matter ischemic lesions [85].
Of note, a vertebrobasilar enlargement can be accessed in a routine MRI evaluation (time-of-flight
sequences), with no time-consuming quality, no contrast need and with high reproducibility.
Increased signal intensity in the pulvinar region on T1-weighted MRI scans (the pulvinar sign)
has been described in patients with AFD [86]. Although characteristic, it is not pathognomonic of this
disease. It is frequently found in male patients and usually affects both thalami, although a unilateral
presentation has also been reported. It seems to be present in less than 20% of the patients with AFD,
and it is associated with a cardiac and renal dysfunction, but not with stroke [87].
Hippocampus atrophy is another central nervous system (CNS) surrogate image reported in
AFD patients (male) and not associated with ischemic signs, probably reflecting a direct neuronal
involvement. This was described in a small study evaluating mild to moderately affected young
AFD patients with MRI [88]. A small longitudinal study (14 patients, median age 46.1 ± 10.8 years)
demonstrated a significant decline of the hippocampus volumetry (11%) over time, which was not
correlated with an increase in the WML load or in cerebrovascular events [89].
Transcranial Doppler
Transcranial Doppler could also detect abnormalities in the brain arteries typical of the small
vessel disease and an abnormal cerebral autoregulation that may be predictive of future neurovascular
events in patients with AFD. Of note, a study with functional transcranial Doppler revealed a cortical
vascular dysfunction in the territory of the posterior circulation in asymptomatic patients [45].
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Positron Emission Tomography and Magnetic Resonance (PET/MR)
Korsholm et al. studied 40 AFD patients and found that the majority of hypometabolic areas on
PET corresponded to cerebral infarcts or haemorrhages on cerebral MR. No areas of hypermetabolism
were detected on PET. There were few and minor findings only detected on PET (diaschisis, discrete
hypometabolism) by this way, and PET did not provide additional relevant clinical information to
cerebral MR [90].
3. Conclusions
Currently, Lyso-Gb3 is the most promising biomarker to detect AFD patients and to evaluate the
effects of the ERT. It is interesting to note that Lyso-Gb3 may help to confirm the pathogenic mutations,
and it is not associated with an organ involvement. Many other biomarkers were found to be related
to specific organ involvement, but few of these were studied to evaluate the response to ERT.
To detect renal involvement, proteinuria and creatinine are still the most important biomarkers,
although efforts have been made to find biomarkers that allow early diagnosis of renal impairment.
In the future, podocyturia may be another promising marker of glomerular damage and ERT response.
Additionally, increased excretion of some tubular proteins has been related to early renal damage.
Cardiac involvement is best diagnosed with new echocardiographic and cardiac resonance
techniques, and specific patterns have been described as associated with incipient and late lesions.
Moreover, higher levels of troponin I and Hs-cTnT were correlated with cardiac lesions of AFD. No
correlation of these imaging and serum biomarkers were related to ERT.
To detect cerebrovascular involvement, typical imaging findings are the most important, but they
do not allow assessment of the ERT response. Studies developed in proteomics and metabolomics could
give us some kind of fingerprint of the AFD, that could help us in the diagnosis and in the follow-up
of the AFD patients. Moreover, we expect that future studies will relate cardiac and cerebrovascular
imaging findings with ERT response.
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